Cancer immunotherapy using a potent immunodominant CTL epitope

Liwen Song, Ming Chieh Yang, Jayne Knoff, Zu Yue Sun, Tzyy Choou Wu, Chien-Fu Hung

Research output: Contribution to journalArticle

Abstract

Immunotherapy has emerged as a promising approach that can be used in conjunction with conventional chemotherapy and radiotherapy to further improve the survival rate of patients with advanced cancer. We have recently shown in previous studies that chemotherapy and radiation therapy can alter the tumor microenvironment and allow intratumoral vaccination to prime the adaptive immune system leading to the generation of antigen-specific cell-mediated immune responses. Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas-FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.

Original languageEnglish (US)
Pages (from-to)6039-6048
Number of pages10
JournalVaccine
Volume32
Issue number46
DOIs
StatePublished - Oct 21 2014

Fingerprint

Immunodominant Epitopes
immunotherapy
Immunotherapy
neoplasms
Cisplatin
cisplatin
Neoplasms
drug therapy
Drug Therapy
Radiotherapy
radiotherapy
antigens
Cross-Priming
cell-mediated immunity
Antigens
Tumor Microenvironment
Neoplasm Antigens
Therapeutics
Immune System
Vaccination

Keywords

  • Cisplatin
  • Immunodominant CTL epitope
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Cancer immunotherapy using a potent immunodominant CTL epitope. / Song, Liwen; Yang, Ming Chieh; Knoff, Jayne; Sun, Zu Yue; Wu, Tzyy Choou; Hung, Chien-Fu.

In: Vaccine, Vol. 32, No. 46, 21.10.2014, p. 6039-6048.

Research output: Contribution to journalArticle

Song, Liwen ; Yang, Ming Chieh ; Knoff, Jayne ; Sun, Zu Yue ; Wu, Tzyy Choou ; Hung, Chien-Fu. / Cancer immunotherapy using a potent immunodominant CTL epitope. In: Vaccine. 2014 ; Vol. 32, No. 46. pp. 6039-6048.
@article{063d8f0d80b344d0bd56823a2e817e90,
title = "Cancer immunotherapy using a potent immunodominant CTL epitope",
abstract = "Immunotherapy has emerged as a promising approach that can be used in conjunction with conventional chemotherapy and radiotherapy to further improve the survival rate of patients with advanced cancer. We have recently shown in previous studies that chemotherapy and radiation therapy can alter the tumor microenvironment and allow intratumoral vaccination to prime the adaptive immune system leading to the generation of antigen-specific cell-mediated immune responses. Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas-FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.",
keywords = "Cisplatin, Immunodominant CTL epitope, Immunotherapy",
author = "Liwen Song and Yang, {Ming Chieh} and Jayne Knoff and Sun, {Zu Yue} and Wu, {Tzyy Choou} and Chien-Fu Hung",
year = "2014",
month = "10",
day = "21",
doi = "10.1016/j.vaccine.2014.09.021",
language = "English (US)",
volume = "32",
pages = "6039--6048",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "46",

}

TY - JOUR

T1 - Cancer immunotherapy using a potent immunodominant CTL epitope

AU - Song, Liwen

AU - Yang, Ming Chieh

AU - Knoff, Jayne

AU - Sun, Zu Yue

AU - Wu, Tzyy Choou

AU - Hung, Chien-Fu

PY - 2014/10/21

Y1 - 2014/10/21

N2 - Immunotherapy has emerged as a promising approach that can be used in conjunction with conventional chemotherapy and radiotherapy to further improve the survival rate of patients with advanced cancer. We have recently shown in previous studies that chemotherapy and radiation therapy can alter the tumor microenvironment and allow intratumoral vaccination to prime the adaptive immune system leading to the generation of antigen-specific cell-mediated immune responses. Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas-FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.

AB - Immunotherapy has emerged as a promising approach that can be used in conjunction with conventional chemotherapy and radiotherapy to further improve the survival rate of patients with advanced cancer. We have recently shown in previous studies that chemotherapy and radiation therapy can alter the tumor microenvironment and allow intratumoral vaccination to prime the adaptive immune system leading to the generation of antigen-specific cell-mediated immune responses. Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas-FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.

KW - Cisplatin

KW - Immunodominant CTL epitope

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84907970874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907970874&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.09.021

DO - 10.1016/j.vaccine.2014.09.021

M3 - Article

C2 - 25245934

AN - SCOPUS:84907970874

VL - 32

SP - 6039

EP - 6048

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 46

ER -